ProCE Banner Activity

CME

Hot Topics in Heart Failure: New Data and Therapies That Are Changing the Treatment Landscape

Hear these expert faculty as they discuss questions such as, “Do outcomes from DAPA-HF and EMPEROR-Reduced suggest a class effect of SGLT2 inhibitors?” “Is it safe to start ARNI in the hospital, and does it influence post discharge outcomes?” “What is the likely place of emerging therapies like vericiguat and omecamtiv mecarbil in HFrEF?”

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: December 15, 2020

Expiration: December 14, 2021

No longer available for credit.

Share

Faculty

Deepak L. Bhatt

Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC

Executive Director, Interventional Cardiovascular Programs
Brigham and Womens Hospital Heart & Vascular Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Javed Butler

Javed Butler, MD, MPH, MBA

President
Baylor Scott and White Research Institute
Dallas, Texas
Distinguished Professor of Medicine
Department of Medicine
University of Mississippi Medical Center
Jackson, Mississippi

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

This educational activity is supported by an educational grant from

Merck

Target Audience

This activity is intended for cardiologists, hospitalists, internists, and other healthcare providers who treat patients with heart failure.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Summarize new data from PIONEER-HF regarding timing of initiation of patients receiving ARNIs who have experienced acute decompensated HF
  • Describe the expected benefits on SGLT2 inhibitors in patients with HF
  • Summarize clinical trial data regarding investigational treatments for patients with HFrEF

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty Disclosure

Primary Author

Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC

Executive Director, Interventional Cardiovascular Programs
Brigham and Womens Hospital Heart & Vascular Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC, has received funds for research support from Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, Chiesi, CSL Behring, Eisai, Ethicon, Ferring, Forest Laboratories, Fractyl, Idorsia, Ironwood, Ischemix, Lexicon, Lilly, Medtronic, Pfizer, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi Aventis, Synaptic, and The Medicines Company.

Javed Butler, MD, MPH, MBA

President
Baylor Scott and White Research Institute
Dallas, Texas
Distinguished Professor of Medicine
Department of Medicine
University of Mississippi Medical Center
Jackson, Mississippi

Javed Butler, MD, MPH, MBA, has disclosed that he has received consulting fees from Abbott, Amgen, Applied Therapeutics, Array, AstraZeneca, Bayer, Boehringer Ingelheim, CVRx, G3 Pharma, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Relypsa, Sequana Medical, V-Wave Limited, and Vifor and fees for non-CME/CE services from AstraZeneca, Boehringer Ingelheim/Lilly, Janssen, and Novartis.

Staff Disclosure

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.

Zachary Schwartz, MSc, ELS

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.

Carolyn Skowronski, PharmD

Associate Director, Scientific Services

Carolyn Skowronski, PharmD, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 15, 2020, through December 14, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this program is to improve the knowledge and competence of cardiologists, internists, hospitalists, and other clinicians on new and emerging treatment strategies to reduce HF-related hospitalization and death.